Dr. Mesa on Mitigating Racial Disparities in MPN Clinical Trials

Video

In Partnership With:

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses mitigating racial disparities in myeloproliferative neoplasm (MPN) clinical trials.

In myelofibrosis, a clinical trial that included patients from China provided key insight on how different patient populations respond to treatment, explains Mesa.

Moreover, this trial provided data on why some populations experience higher rates of anemia compared with others​, Mesa says.

As the MPN space continues to expand, further diversifying accrual to clinical trials could potentially increase the chances of finding a cure ​for these diseases; however, teamwork is paramount, ​Mesa concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH